17Jan/14

Gilead's Hep C Drug Sovaldi Approved in EU – Drug Discovery & Development


Drug Discovery & Development

Gilead’s Hep C Drug Sovaldi Approved in EU
Drug Discovery & Development
Sovaldi has been studied in hepatitis C virus (HCV) genotypes 1-6. The efficacy of Sovaldi has been established in patients with genotypes 1-4, in those awaiting liver transplantation and those with HCV/HIV-1 co-infection. The clinical data supporting
Sovaldi OK’d for marketing throughout European UnionHealio

all 17 news articles »